Author
1. Sardana Kabir
2. De Dipankar
3. Narang Isha
4. Bhushan Bharat
5. Mehta Hitaishi
6. Joshi Devesh Kumar
7. Arora Sandep
ISBN
9789390281367
DOI
10.5005/jp/books/18712_8
Edition
2/e
Publishing Year
2022
Pages
165
Author Affiliations
1.
Dr Ram Manohar Lohia Hospital and Post Graduate Institute of Medical Education and Research, New Delhi, India,
ABVIMS and Dr RML Hospital, New Delhi, India; Guru Gobind, Singh Indraprastha University, Delhi; Delhi, University; Maulana Azad Medical College, New Delhi, India,
Maulana Azad Medical College and Lok Nayak Hospital New Delhi, India, e-mail: kabirijdvl@gmail.com
2.
Post Graduate Institute of Medical Education and Research, Chandigarh, India,
Postgraduate Institute of Medical, Education and Research, Chandigarh, India,
Postgraduate Institute of Medical Education and Research, Chandigarh, India, dr_dipankar_de@yahoo.in,
Postgraduate Institute of Medical, Education and Research, Chandigarh, India, dr_dipankar_de@yahoo.in,
Postgraduate Institute of Medical Education and Research, Chandigarh, India, e-mail: chhinu75@yahoo.co.in,
Postgraduate Institute of Medical Education and Research, Chandigarh, India,
Postgraduate Institute of Medical Education and Research, Chandigarh,
Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
3.
Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India,
University Hospitals of Derby and Burton, United Kingdom,
Maulana Azad Medical College, New Delhi, India,
University Hospitals of Derby and Burton, Derby, United Kingdom
4.
Department of Neurology, GMC Kota, Chomu, Jaipur, Rajasthan, India,
Novartis, India, Mumbai, Maharashtra, India
5.
Postgraduate Institute of Medical Education and Research,
Chandigarh, India,
Postgraduate Institute of Medical Education and Research, Chandigarh, India
6.
Zydus
7.
Army College of Medical Sciences, Delhi Cantonment, New Delhi, India
Chapter keywords
Biological drug,
dermatology,
psoriasis,
adalimumab,
infliximab,
etanercept,
certolizumab pegol,
interleukin-17 antagonists,
secukinumab,
ixekizumab,
ustekinumab,
rituximab,
anti-immunoglobulin E biologicals,
omalizumab,
dupilumab,
tofacitinib citrate,
apremilast
